Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Olita (olmutinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Hanmi

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	olmutinib Sensitive: C2 – Inclusion Criteria olmutinib Sensitive : C2	olmutinib Sensitive: C2 – Inclusion Criteria olmutinib Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3